Pharma Focus Asia

Ambient Stable Biologics - Stable Aqueous Erythropoietin

Challenge

Erythropoietin (EPO) is known to aggregate under heat stress, which prevents storage of liquid compositions at ambient temperature. The key challenge of this study was to demonstrate that the application of the ArestatT tools can reduce significantly aggregation of EPO at an elevated temperature, compared with a marketed liquid formulation

ArestatT solution

A liquid EPO product was reformulated and the key parameters, such as pH, osmolality and the nature of the surfactant were kept unchanged in the new formulation. The critical change was the nature of the buffering species, which were selected to ensure minimal proton exchange between the protein molecule and excipients, and to minimise hydrophobic interactions. Incubation of the currently marketed EPO formulation at 40?C for 24 weeks resulted in considerable (>50%) high molecular weight species formation (HMWS, measured by size-exclusion chromatography). In contrast, the reformulated EPO, using the ArestatT alternative buffering species, showed virtually no aggregation following the same treatment.

The rate of aggregation of EPO (82 ?g/ml) at 40&deh;C in ArestatT formulation compared with the control.

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024